Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine, Nanjing, 210002, China.
BMC Nephrol. 2012 Sep 28;13:128. doi: 10.1186/1471-2369-13-128.
Since the term chronic allograft nephropathy (CAN) was removed from the Banff scheme in 2005, transplant glomerulopathy (TG) has been regarded as a clinicopathological entity that is one of the major causes of graft loss. To assess the distinction between CAN and TG, we performed a comprehensive evaluation comparing TG with traditional CAN.
We compared the clinicopathological features of 43 cases of TG with 43 matched cases of non-TG CAN (non-TG group) after renal transplantation. TG was diagnosed by light microscopy based on the double contours of the glomerular basement membranes, and the Banff 97 classification system was used to score TG severity (cg0-3).
Compared to the control group, we found a significantly higher incidence of positivity for human leukocyte antigen class-I and II antibodies, a higher incidence of hepatitis C virus (HCV) infection, and poorer graft survival in TG patients. Clinically, TG was associated with a higher prevalence of proteinuria, hematuria, anaemia and hypoalbuminemia. Histologically, TG strongly correlated with antibody related microcirculatory injuries, including glomerulitis, peritubular capillaritis and peritubular capillary (PTC) C4d deposition. Interestingly, the TG patients showed a significantly higher incidence of IgA deposition than the control patients. C4d-positive TG was correlated with higher TG and PTC scores, and PTC C4d deposition was correlated with a more rapid progression to graft dysfunction. TG accompanied by HCV infection was associated with heavier proteinuria, higher TG and C4d scores, and poorer graft survival.
TG presents clinicopathological features that are distinct from non-TG cases and leads to poorer outcomes. PTC C4d deposition is related to a more rapid progression to graft loss, suggesting ongoing antibody reactivity. HCV-positive TG is a more severe sub-entity, that requires further investigation.
自 2005 年 Banff 方案中删除慢性移植肾肾病(CAN)这一术语以来,移植肾小球病(TG)已被视为导致移植物丢失的主要原因之一的临床病理实体。为了评估 CAN 和 TG 之间的区别,我们对 TG 与传统 CAN 进行了综合评估。
我们比较了 43 例 TG 患者和 43 例匹配的非 TG-CAN(非 TG 组)患者的临床病理特征。TG 通过肾小球基底膜的双轮廓在光镜下诊断,并使用 Banff 97 分类系统对 TG 严重程度(cg0-3)进行评分。
与对照组相比,我们发现 TG 患者 HLA Ⅰ类和Ⅱ类抗体阳性率显著升高,丙型肝炎病毒(HCV)感染率较高,移植物存活率较低。临床上,TG 与蛋白尿、血尿、贫血和低白蛋白血症的发生率较高有关。组织学上,TG 与抗体相关的微小循环损伤密切相关,包括肾小球肾炎、肾小管周毛细血管炎和肾小管周毛细血管(PTC)C4d 沉积。有趣的是,TG 患者的 IgA 沉积发生率明显高于对照组。C4d 阳性 TG 与更高的 TG 和 PTC 评分相关,而 PTC C4d 沉积与更快进展至移植物功能障碍相关。伴有 HCV 感染的 TG 与更严重的蛋白尿、更高的 TG 和 C4d 评分以及较差的移植物存活率相关。
TG 表现出与非 TG 病例不同的临床病理特征,并导致较差的结果。PTC C4d 沉积与更快进展至移植物丢失相关,提示持续的抗体反应。HCV 阳性 TG 是一种更严重的亚实体,需要进一步研究。